TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.¹

Click here for additional safety information and for a link to the TRUQAP Product Monograph discussing:

• The most serious warning and precaution regarding cutaneous adverse reactions, hyperglycemia, and severe diarrhea.
• Other relevant warnings and precautions regarding caution when driving or operating machinery, testing for FG levels and HbA1c, monitoring of ketones, use of effective contraception, pregnancy, breastfeeding, and teratogenic risk.
• Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

The Product Monograph is also available through our medical department. Call us at 1-800-668-6000.